Guggenheim initiated coverage on Revvity
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
Guggenheim initiated coverage of Revvity with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/26/2026 | $115.00 | Mkt Perform | Bernstein |
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/14/2026 | $95.00 | Overweight → Equal Weight | Barclays |
| 12/15/2025 | $110.00 | Buy → Neutral | BofA Securities |
| 12/9/2025 | $105.00 | Neutral | Goldman |
| 10/16/2025 | Neutral | Guggenheim | |
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
Revvity, Inc. (NYSE:RVTY) today published its 2026 Impact Report, highlighting the Company’s sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Singh, president and chief executive officer at Revvity. "We are proud of the progress we've made advancing our environmental, social and governance priorities, from strengthening transparency and environmental stewardship to expanding
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workfl
New MCP connector extends Signals AI beyond the Signals One platform, enabling scientists to interact with connected R&D knowledge through Claude Claude accesses scientific data and organizational knowledge through Signals' intelligence layer, improving context-aware analysis and decision-making Collaboration combines industry-leading AI capabilities with trusted scientific workflows to help accelerate research and development Revvity, Inc. (NYSE:RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, inc
11-K - REVVITY, INC. (0000031791) (Filer)
SD - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
Bernstein resumed coverage of Revvity with a rating of Mkt Perform and set a new price target of $115.00
Wolfe Research resumed coverage of Revvity with a rating of Peer Perform
Barclays downgraded Revvity from Overweight to Equal Weight and set a new price target of $95.00
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workfl
Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)